Table 1.
Open in new tab

Baseline Demographics

Baseline Characteristicsn = 152 (100%)
Gender
    Female86 (56.6%)
    Male66 (43.4%)
Age at diagnosis, y
    Mean ± SD48 ± 17.1
    Range9–85
Age at I-131 treatment
    Mean ± SD53.3 ± 18.4
    Range18–86
Surgery
    Total thyroidectomy152 (100%)
Histology
    Papillary114 (75%)
        Classical70 (46%)
        Follicular variant22 (14.5%)
        Tall cell9 (5.9%)
    Follicular22 (14.5%)
    Hürthle cell10 (6.6%)
    Poorly differentiated6 (3.9%)
TNM stage
    I53 (34.9%)
    II10 (6.6%)
    III27 (17.7%)
    IV62 (40.8%)
Method of preparation
    rhTSH110 (59.5%)
    THW75 (40.5%)
Administered I-131 activity, mCi
    Mean ± SD262.1 ± 100.8
    Range26.4–499
Cumulative dosage of I-131 received, mCi
    Mean ± SD448.9 ± 269.9
    Range26.4–1417
Ratio of administered I-131 activity to MTA
    Mean ± SD68% ± 22%
    Range4%–100%
EBRT
    Yes25 (16.4%)
    No127 (83.6%)
Baseline Characteristicsn = 152 (100%)
Gender
    Female86 (56.6%)
    Male66 (43.4%)
Age at diagnosis, y
    Mean ± SD48 ± 17.1
    Range9–85
Age at I-131 treatment
    Mean ± SD53.3 ± 18.4
    Range18–86
Surgery
    Total thyroidectomy152 (100%)
Histology
    Papillary114 (75%)
        Classical70 (46%)
        Follicular variant22 (14.5%)
        Tall cell9 (5.9%)
    Follicular22 (14.5%)
    Hürthle cell10 (6.6%)
    Poorly differentiated6 (3.9%)
TNM stage
    I53 (34.9%)
    II10 (6.6%)
    III27 (17.7%)
    IV62 (40.8%)
Method of preparation
    rhTSH110 (59.5%)
    THW75 (40.5%)
Administered I-131 activity, mCi
    Mean ± SD262.1 ± 100.8
    Range26.4–499
Cumulative dosage of I-131 received, mCi
    Mean ± SD448.9 ± 269.9
    Range26.4–1417
Ratio of administered I-131 activity to MTA
    Mean ± SD68% ± 22%
    Range4%–100%
EBRT
    Yes25 (16.4%)
    No127 (83.6%)
Table 1.
Open in new tab

Baseline Demographics

Baseline Characteristicsn = 152 (100%)
Gender
    Female86 (56.6%)
    Male66 (43.4%)
Age at diagnosis, y
    Mean ± SD48 ± 17.1
    Range9–85
Age at I-131 treatment
    Mean ± SD53.3 ± 18.4
    Range18–86
Surgery
    Total thyroidectomy152 (100%)
Histology
    Papillary114 (75%)
        Classical70 (46%)
        Follicular variant22 (14.5%)
        Tall cell9 (5.9%)
    Follicular22 (14.5%)
    Hürthle cell10 (6.6%)
    Poorly differentiated6 (3.9%)
TNM stage
    I53 (34.9%)
    II10 (6.6%)
    III27 (17.7%)
    IV62 (40.8%)
Method of preparation
    rhTSH110 (59.5%)
    THW75 (40.5%)
Administered I-131 activity, mCi
    Mean ± SD262.1 ± 100.8
    Range26.4–499
Cumulative dosage of I-131 received, mCi
    Mean ± SD448.9 ± 269.9
    Range26.4–1417
Ratio of administered I-131 activity to MTA
    Mean ± SD68% ± 22%
    Range4%–100%
EBRT
    Yes25 (16.4%)
    No127 (83.6%)
Baseline Characteristicsn = 152 (100%)
Gender
    Female86 (56.6%)
    Male66 (43.4%)
Age at diagnosis, y
    Mean ± SD48 ± 17.1
    Range9–85
Age at I-131 treatment
    Mean ± SD53.3 ± 18.4
    Range18–86
Surgery
    Total thyroidectomy152 (100%)
Histology
    Papillary114 (75%)
        Classical70 (46%)
        Follicular variant22 (14.5%)
        Tall cell9 (5.9%)
    Follicular22 (14.5%)
    Hürthle cell10 (6.6%)
    Poorly differentiated6 (3.9%)
TNM stage
    I53 (34.9%)
    II10 (6.6%)
    III27 (17.7%)
    IV62 (40.8%)
Method of preparation
    rhTSH110 (59.5%)
    THW75 (40.5%)
Administered I-131 activity, mCi
    Mean ± SD262.1 ± 100.8
    Range26.4–499
Cumulative dosage of I-131 received, mCi
    Mean ± SD448.9 ± 269.9
    Range26.4–1417
Ratio of administered I-131 activity to MTA
    Mean ± SD68% ± 22%
    Range4%–100%
EBRT
    Yes25 (16.4%)
    No127 (83.6%)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close